Induction of apoptosis-resistant and TGF-β-insensitive murine CD8+ cytotoxic T lymphocytes specific for HIV-1 gp160

Cellular Immunology

Volumn 280, Issue 2, 2012, Pages 138-147

  Takaku, Shun ^a   Nakagawa, Yohko ^a   Owaki, Atsuko ^a   Shimizu, Masumi ^a   Takahashi, Megumi ^a   Takahashi, Hidemi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Apoptosis; CTLs; Epitope peptide; HIV; IL 17; IL 6; Tc17; TCR transgenic mice; TGF

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA;

ADOPTIVE TRANSFER; ANIMAL CELL; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; HIV ENVELOPE PROTEIN GP160; INTERLEUKIN-6; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 84873492190     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2012.12.008     Document Type: Article

References (51)

1. Terabe M., Matsui S., Park J.M., Mamura M., Noben-Trauth N., Donaldson D.D., Chen W., Wahl S.M., Ledbetter S., Pratt B., Letterio J.J., Paul W.E., Berzofsky J.A. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 2003, 198:1741-1752.
2. Kobie J.J., Wu R.S., Kurt R.A., Lou S., Adelman M.K., Whitesell L.J., Ramanathapuram L.V., Arteaga C.L., Akporiaye E.T. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res. 2003, 63:1860-1864.
3. Cottrez F., Groux H. Regulation of TGF-beta response during T cell activation is modulated by IL-10. J. Immunol. 2001, 167:773-778.
4. Thomas D.A., Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005, 8:369-380.
5. Li H., Han Y., Guo Q., Zhang M., Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J. Immunol. 2009, 182:240-249.
6. Trotta R., Dal Col J., Yu J., Ciarlariello D., Thomas B., Zhang X., Allard J., Wei M., Mao H., Byrd J.C., Perrotti D., Caligiuri M.A. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J. Immunol. 2008, 181:3784-3792.
7. Li M.O., Flavell R.A. TGF-beta: a master of all T cell trades. Cell 2008, 134:392-404.
8. McCormick C., Freshney R.I. Activity of growth factors in the IL-6 group in the differentiation of human lung adenocarcinoma. Br. J. Cancer 2000, 82:881-890.
9. McCormick C., Freshney R.I., Speirs V. Activity of interferon alpha, interleukin 6 and insulin in the regulation of differentiation in A549 alveolar carcinoma cells. Br. J. Cancer 1995, 71:232-239.
10. Walia B., Wang L., Merlin D., Sitaraman S.V. TGF-beta down-regulates IL-6 signaling in intestinal epithelial cells: critical role of SMAD-2. FASEB J. 2003, 17:2130-2132.
11. Zhang X.L., Topley N., Ito T., Phillips A. Interleukin-6 regulation of transforming growth factor (TGF)-beta receptor compartmentalization and turnover enhances TGF-beta1 signaling. J. Biol. Chem. 2005, 280:12239-12245.
12. + regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 2003, 198:1875-1886.
13. + T cell-mediated suppression by dendritic cells. Science 2003, 299:1033-1036.
14. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., Weiner H.L., Kuchroo V.K. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
15. Liu S.J., Tsai J.P., Shen C.R., Sher Y.P., Hsieh C.L., Yeh Y.C., Chou A.H., Chang S.R., Hsiao K.N., Yu F.W., Chen H.W. Induction of a distinct CD8 Tnc17 subset by transforming growth factor-beta and interleukin-6. J. Leukocyte Biol. 2007, 82:354-360.
16. + T cells display enhanced antitumor immunity. Blood 2009, 114:596-599.
17. Huber M., Heink S., Grothe H., Guralnik A., Reinhard K., Elflein K., Hunig T., Mittrucker H.W., Brustle A., Kamradt T., Lohoff M. A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity. Eur. J. Immunol. 2009, 39:1716-1725.
18. Hamada H., Garcia-Hernandez Mde L., Reome J.B., Misra S.K., Strutt T.M., McKinstry K.K., Cooper A.M., Swain S.L., Dutton R.W. Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J. Immunol. 2009, 182:3469-3481.
19. Yen H.R., Harris T.J., Wada S., Grosso J.F., Getnet D., Goldberg M.V., Liang K.L., Bruno T.C., Pyle K.J., Chan S.L., Anders R.A., Trimble C.L., Adler A.J., Lin T.Y., Pardoll D.M., Huang C.T., Drake C.G. Tc17 CD8 T cells: functional plasticity and subset diversity. J. Immunol. 2009, 183:7161-7168.
20. Yeh N., Glosson N.L., Wang N., Guindon L., McKinley C., Hamada H., Li Q., Dutton R.W., Shrikant P., Zhou B., Brutkiewicz R.R., Blum J.S., Kaplan M.H. Tc17 cells are capable of mediating immunity to vaccinia virus by acquisition of a cytotoxic phenotype. J. Immunol. 2010, 185:2089-2098.
21. Takahashi H., Houghten R., Putney S.D., Margulies D.H., Moss B., Germain R.N., Berzofsky J.A. Structural requirements for class I MHC molecule-mediated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immunodeficiency virus envelope protein. J. Exp. Med. 1989, 170:2023-2035.
22. Yokosuka T., Takase K., Suzuki M., Nakagawa Y., Taki S., Takahashi H., Fujisawa T., Arase H., Saito T. Predominant role of T cell receptor (TCR)-alpha chain in forming preimmune TCR repertoire revealed by clonal TCR reconstitution system. J. Exp. Med. 2002, 195:991-1001.
23. Kuribayashi H., Wakabayashi A., Shimizu M., Kaneko H., Norose Y., Nakagawa Y., Wang J., Kumagai Y., Margulies D.H., Takahashi H. Resistance to viral infection by intraepithelial lymphocytes in HIV-1 P18-I10-specific T-cell receptor transgenic mice. Biochem. Biophys. Res. Commun. 2004, 316:356-363.
24. Takahashi H., Cohen J., Hosmalin A., Cease K.B., Houghten R., Cornette J.L., DeLisi C., Moss B., Germain R.N., Berzofsky J.A. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 1988, 85:3105-3109.
25. Ewen C., Kane K.P., Shostak I., Griebel P.J., Bertram E.M., Watts T.H., Bleackley R.C., McElhaney J.E. A novel cytotoxicity assay to evaluate antigen-specific CTL responses using a colorimetric substrate for Granzyme B. J. Immunol. Meth. 2003, 276:89-101.
26. + HIV-1 envelope-specific murine CTLs by short exposure to antigenic peptide. J. Immunol. 2002, 169:6588-6593.
27. Y. Nakagawa, M. Shimizu, Y. Norose, M. Takahashi, H. Takahashi, Induction of rapid apoptosis for class I MHC molecule-restricted CD8+ HIV-1 gp160-specific murine activated CTLs by free antigenic peptide in vivo, Int. Immunol. (2012) in press.
28. Gallimore A., Glithero A., Godkin A., Tissot A.C., Pluckthun A., Elliott T., Hengartner H., Zinkernagel R. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J. Exp. Med. 1998, 187:1383-1393.
29. + T cell clones during primary HIV infection. Proc. Natl. Acad. Sci. USA 1997, 94:9848-9853.
30. Carmichael A., Jin X., Sissons P., Borysiewicz L. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J. Exp. Med. 1993, 177:249-256.
31. + T cell longevity and avoidance of TRAIL-mediated apoptosis. Proc. Natl. Acad. Sci. USA 2008, 105:5201-5206.
32. + regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur. J. Immunol. 2002, 32:3267-3275.
33. Chen M.L., Pittet M.J., Gorelik L., Flavell R.A., Weissleder R., von Boehmer H., Khazaie K. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc. Natl. Acad. Sci. USA 2005, 102:419-424.
34. Su H.C., Ishikawa R., Biron C.A. Transforming growth factor-beta expression and natural killer cell responses during virus infection of normal, nude, and SCID mice. J. Immunol. 1993, 151:4874-4890.
35. Michelson S., Alcami J., Kim S.J., Danielpour D., Bachelerie F., Picard L., Bessia C., Paya C., Virelizier J.L. Human cytomegalovirus infection induces transcription and secretion of transforming growth factor beta 1. J. Virol. 1994, 68:5730-5737.
36. Gibbs J.D., Ornoff D.M., Igo H.A., Zeng J.Y., Imani F. Cell cycle arrest by transforming growth factor beta1 enhances replication of respiratory syncytial virus in lung epithelial cells. J. Virol. 2009, 83:12424-12431.
37. Mendez-Samperio P., Hernandez M., Ayala H.E. Induction of transforming growth factor-beta 1 production in human cells by herpes simplex virus. J. Interferon Cytokine Res. 2000, 20:273-280.
38. Kekow J., Wachsman W., McCutchan J.A., Cronin M., Carson D.A., Lotz M. Transforming growth factor beta and noncytopathic mechanisms of immunodeficiency in human immunodeficiency virus infection. Proc. Natl. Acad. Sci. USA 1990, 87:8321-8325.
39. Terabe M., Matsui S., Noben-Trauth N., Chen H., Watson C., Donaldson D.D., Carbone D.P., Paul W.E., Berzofsky J.A. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 2000, 1:515-520.
40. Nam J.S., Terabe M., Kang M.J., Chae H., Voong N., Yang Y.A., Laurence A., Michalowska A., Mamura M., Lonning S., Berzofsky J.A., Wakefield L.M. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res. 2008, 68:3915-3923.
41. Wallace A., Kapoor V., Sun J., Mrass P., Weninger W., Heitjan D.F., June C., Kaiser L.R., Ling L.E., Albelda S.M. Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin. Cancer Res. 2008, 14:3966-3974.
42. + T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody. Clin. Cancer Res. 2009, 15:6560-6569.
43. Ueda R., Fujita M., Zhu X., Sasaki K., Kastenhuber E.R., Kohanbash G., McDonald H.A., Harper J., Lonning S., Okada H. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin. Cancer Res. 2009, 15:6551-6559.
44. Takaku S., Terabe M., Ambrosino E., Peng J., Lonning S., McPherson J.M., Berzofsky J.A. Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells. Int. J. Cancer 2010, 126:1666-1674.
45. Hsiao Y.W., Liao K.W., Hung S.W., Chu R.M. Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokine-activated killing activity. J. Immunol. 2004, 172:1508-1514.
46. Ohta K., Yamagami S., Taylor A.W., Streilein J.W. IL-6 antagonizes TGF-beta and abolishes immune privilege in eyes with endotoxin-induced uveitis. Invest. Ophthalmol. Vis. Sci. 2000, 41:2591-2599.
47. + T cells: eradication of autologous mouse prostate cancer. Cancer Res. 2005, 65:1761-1769.
48. + T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells. Prostate 2006, 66:235-247.
49. Qin W., Tian F., Wang F., Song B., Wang H., Zhang Q., Jovanovic B., Liang L., Guo Y., Smith N., Lee C. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive cytolytic T cells for treatment of established mouse renca tumors. Urology 2008, 72:943-947.
50. + T cells. Clin. Cancer Res. 2010, 16:164-173.
51. Quatromoni J.G., Wang Y., Vo D.D., Morris L.F., Jazirehi A.R., McBride W., Chatila T., Koya R.C., Economou J.S. T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFbeta) signaling mediate superior tumor regression in an animal model of adoptive cell therapy. J. Transl. Med. 2012, 10:127.